Sai Life SciencesNSE:SAILIFE +1.56%18 Days Payable is 74.74 as of Mar. 2026, which is 12% below its 10-year median of 84.76. GuruFocus rates NSE:SAILIFE with a GF Score™ of 18/100. The stock has 5 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, Sai Life Sciences ranks better than 56.32% on this metric.
The historical rank and industry rank for Sai Life Sciences's Days Payable or its related term are showing as below:
NSE:SAILIFE'
s Days Payable Range Over the Past 10 Years
Min: 65.46 Med: 84.76 Max: 120.75
Current: 82.74
During the past 5 years, Sai Life Sciences's highest Days Payable was 120.75. The lowest was 65.46. And the median was 84.76.
NSE:SAILIFE's Days Payable is ranked better than 56.32% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 65.385
vs NSE:SAILIFE: 82.74
Sai Life Sciences's Days Payable
declined
from Mar. 2025 (92.31) to Mar. 2026 (74.74).
It may suggest that Sai Life Sciencesaccelerated paying its suppliers.
Sai Life Sciences Days Payable Related Terms
Sai Life Sciences Days Payable Historical Data
* Premium members only.
The historical data trend for Sai Life Sciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:SAILIFE vs TMO, DHR, IDXX: Days Payable Comparison
For the Diagnostics & Research subindustry, Sai Life Sciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sai Life Sciences Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Sai Life Sciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Sai Life Sciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Sai Life Sciences's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sai Life Sciences (NSE:SAILIFE) has a Days Payable of 74.74 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sai Life Sciences and its competitors. This is 12% below median its historical median of 84.76. Over the past decade, Sai Life Sciences' Days Payable has ranged from 65.46 to 120.75. According to the industry distribution chart, Sai Life Sciences ranks #83 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 43.7%.
Is Sai Life Sciences' Days Payable too high?
Sai Life Sciences' current Days Payable of 74.74 is 12% below median its 10-year median of 84.76. Over the past 10 years, this metric has ranged from a low of 65.46 to a high of 120.75. The Medical Diagnostics & Research industry median Days Payable is 65.39. Sai Life Sciences' value of 74.74 is 14.3% above this industry median. Based on the distribution chart, Sai Life Sciences ranks #83 out of 190 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Sai Life Sciences has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sai Life Sciences' Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Sai Life Sciences ranks #83 out of 190 companies for Days Payable. This puts Sai Life Sciences in the upper half of its industry. The industry median Days Payable is 65.39. Sai Life Sciences' value of 74.74 is 14.3% above this benchmark. Historically, Sai Life Sciences' own Days Payable has ranged from 65.46 to 120.75 over the past decade. While the company's 10-year median is 84.76 vs. the industry median of 65.39, Sai Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 65.39, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sai Life Sciences's current Days Payable of 74.74 is 14.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sai Life Sciences and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 65.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sai Life Sciences's current Days Payable is 74.74, which is 12% below median its own 10-year median of 84.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Life Sciences stock overvalued right now?
Sai Life Sciences (NSE:SAILIFE) has a current Days Payable of 74.74. The current Days Payable is 74.74, which is 12% below median its 10-year median of 84.76 and 14.3% above the Medical Diagnostics & Research industry median of 65.39. Sai Life Sciences' overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Sai Life Sciences (NSE:SAILIFE), the current Days Payable is 74.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sai Life Sciences Ltd is an innovator-focused, contract research, development, and manufacturing organization. It provides end-to-end services across the drug discovery, development, and manufacturing value chain, for small molecule new chemical entities (NCE), to pharmaceutical innovator companies and biotechnology firms. It possesses both; discovery/contract research (CRO) and chemistry, manufacturing, and control (CMC)/contract development and manufacturing organization (CDMO) capabilities. The company has only one reportable segment: contract research, development, and manufacturing. Geographically it operates in India as well as Outside India.
18GF Score
Get the complete analysis for NSE:SAILIFE
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SAILIFE has been successfully added to your 
